Summary

TB-500 Forte is a commercial variant of TB-500 (synthetic Thymosin Beta-4) marketed by some research peptide vendors as an enhanced formulation, typically containing 10 mg per vial rather than the standard 2-5 mg. The active ingredient is identical to standard TB-500 (Thymosin Beta-4, fragment LKKTETQ). The 'Forte' designation refers to product concentration and packaging, not a different peptide. All research evidence, mechanism, and safety considerations are the same as for standard TB-500.

Mechanism

The mechanism of action of TB-500 Forte is identical to standard TB-500, as the active ingredient is the same peptide (Thymosin Beta-4, fragment LKKTETQ). Thymosin Beta-4 binds G-actin, promotes cell migration and wound healing, stimulates angiogenesis, and exhibits anti-inflammatory properties through NF-kB pathway inhibition. The 'Forte' designation refers to product concentration/packaging, not a different mechanism. See the TB-500 compound profile for full mechanism details.

Protocols

Protocols for TB-500 Forte are the same as standard TB-500 with adjustments for vial size. Typical research protocol: 2-5 mg per week via subcutaneous injection, divided into 1-2 doses. 10 mg vials are reconstituted in 2-4 mL of bacteriostatic water (2.5-5 mg/mL concentration). Common cycle length: 4-6 weeks. All doses for research reference only - no human consumption or medical use is implied.

Work out the draw →

TB-500 Forte has the same legal status as standard TB-500 in the UK. Not a controlled substance, not MHRA-approved, sold for research purposes only. The MHRA has taken enforcement action against vendors marketing peptide products for human use. WADA prohibits Thymosin Beta-4 in competitive sport. The 'Forte' designation does not change the legal status.

References

  1. Goldstein AL, et al. Thymosin beta4: a new peptide therapeutic for wound repair. Ann N Y Acad Sci. 2012;1269:56-62. doi:10.1111/j.1749-6632.2012.06732.x
  2. Philp D, et al. Thymosin beta4 promotes hair growth in normal rats and mice. PLoS One. 2007;2(10):e1009. doi:10.1371/journal.pone.0001009
  3. Bock-Marquette I, et al. Thymosin beta4 acts through Wnt to restore cardiac function. Mol Ther. 2010;18(8):1431-1432. doi:10.1038/mt.2010.137
  4. Smart N, et al. Thymosin beta4 facilitates epicardial neovascularisation. Mol Ther. 2011;19(7):1314-1321. doi:10.1038/mt.2011.45
  5. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:315-325. doi:10.1196/annals.1415.020